Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
January 04, 2023 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
December 23, 2022 08:00 ET
|
Immutep Limited
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population...
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
December 08, 2022 08:00 ET
|
Immutep Limited
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi Biologics SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM;...
Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
December 06, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing...
Immutep to Participate in The JMP Securities Hematology and Oncology Summit
December 02, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer
November 29, 2022 08:00 ET
|
Immutep Limited
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab...
Immutep Receives Australian R&D Tax Incentive
November 14, 2022 08:00 ET
|
Immutep Limited
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce...
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
November 10, 2022 11:10 ET
|
Immutep Limited
Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across...
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
November 10, 2022 09:00 ET
|
Immutep Limited
Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC...
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
November 09, 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...